Kyverna Therapeutics (KYTX) Shares Outstanding (Weighted Average) (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Shares Outstanding (Weighted Average) data on file, last reported at $60.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 39.84% year-over-year to $60.4 million; the trailing twelve-month figure through Mar 2026 stood at $60.4 million (up 39.84% YoY), and the FY2025 full-year result was $44.3 million, up 15.46% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $60.4 million, up from $44.3 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $60.4 million in Q1 2026 and bottomed at $599917.0 in Q2 2023.
• The 4-year median for Shares Outstanding (Weighted Average) is $43.1 million (2024), against an average of $29.7 million.
• The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) jumped 7088.61%; it then grew 0.23% in 2025.
• A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $673622.0 in 2023, then surged by 5590.81% to $38.3 million in 2024, then increased by 15.46% to $44.3 million in 2025, then jumped by 36.54% to $60.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $60.4 million (Q1 2026), $44.3 million (Q4 2025), and $43.3 million (Q3 2025), per Business Quant data.

Peer Comparison